Celltrion’s biosimilar ‘Truxima’ acquires approval in Australia

Celltrion announced the company acquired approval of Truxima(generic name: rituximab), an antibody biosimilar for the treatment of hematologic malignancy, from the Australian Therapeutic Goods Administration on the 20^th.

‘Truxima’ developed by Celltrion is an antibody biosimilar for the treatment of types of hematologic malignancy, such as non-Hodgkin’s lymphoma and rheumatoid arthritis. The o...